Week of Jul 18–24, 2026
Weekly GLP-1 trial and regulatory updates
Read the public weekly current-awareness feed for changes across GLP-1 and related obesity-drug trials, results, regulatory events, and industry news. Three trial drill-downs are free. Deeper trial drill-down is available with the Plus tier. For focused analysis and context, read the GLP-1 Observer newsletter ↗
New to the mechanism classes? See the GLP-1 Field Guides for plain-English explainers on mono, dual, triple, and combination incretin drugs.
This Week's Highlights
- Eli Lilly's retatrutide achieves 22.6% weight loss in Phase 3 TRIUMPH-3 trialResults
- Novo Nordisk takes oral amycretin (zenagamtide) into Phase 3 with 950-patient AMAZE 9New Trial
- Novo Nordisk sues Eli Lilly over allegedly false GLP-1 efficacy advertisements↗News
- Roche discontinues GLP-1/GIP agonist CT-868 to prioritize once-weekly enicepatide↗News
- Samsung Biologics bids $1.8B for PolyPeptide to expand GLP-1 manufacturing capacity↗News
Detailed Updates
Click an NCT badge to open the trial detail drawer.otherFDA/Center for Research on Complex Generics (CRCG) Workshop on Navigating the GLP-1 Generic Drug Pathway - 09/23/2026
Source ↗The FDA and CRCG will host a September 2026 workshop to discuss product development and regulatory assessment considerations for generic GLP-1 receptor agonists.
Phase 3ENDPOINT METEli Lilly's Retatrutide successful in TRIUMPH-3 Phase 3 trial, delivering significant weight loss in adults with severe obesity and established cardiovascular disease
Eli Lilly's triple-agonist retatrutide met its primary endpoint in the Phase 3 TRIUMPH-3 trial, demonstrating up to 22.6% weight reduction at 80 weeks in adults with severe obesity and established cardiovascular disease.
Phase 3ENDPOINT METEli Lilly's Retatrutide meets primary endpoint in TRIUMPH-2 Phase 3 trial, showing significant weight loss and glycemic improvements in adults with type 2 diabetes and obesity/overweight.
Eli Lilly announced that retatrutide met its primary endpoint in the Phase 3 TRIUMPH-2 trial, achieving substantial, dose-dependent weight loss and improved glycemic control at 80 weeks in adults with type 2 diabetes and obesity.
Phase 3Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
Pfizer
Status: RECRUITING → ACTIVE_NOT_RECRUITING
Phase 3A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Eli Lilly and Company
Status: RECRUITING → ACTIVE_NOT_RECRUITING
Phase 3A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects
Fujian Shengdi Pharmaceutical Co., Ltd.
Status: NOT_YET_RECRUITING → RECRUITING
Also: PrimaryCompletionDateChanged (+122 days); CompletionDateChanged (+121 days)
Phase 3A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
Eli Lilly and Company
ResultsPosted: False → True
Phase 2A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes Mellitus
Fujian Shengdi Pharmaceutical Co., Ltd.
Status: NOT_YET_RECRUITING → RECRUITING
Phase 1A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or Overweight
Boehringer Ingelheim
Status: NOT_YET_RECRUITING → RECRUITING
Phase 1A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
Boehringer Ingelheim
Status: RECRUITING → ACTIVE_NOT_RECRUITING
Phase 1Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity
Amgen
Status: RECRUITING → ACTIVE_NOT_RECRUITING
Roche cans one Carmot obesity asset as another shows best-in-class potential
Source ↗Roche has dropped development of its once-daily GLP-1/GIP receptor agonist CT-868 to strategically prioritize enicepatide, a once-weekly dual agonist targeting both obesity and Type 1 diabetes.
Also covered by: fierce_biotech
Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesity
Source ↗Samsung Biologics has proposed a $1.8 billion acquisition of Swiss peptide manufacturer PolyPeptide to expand its manufacturing capacity for GLP-1 and obesity therapies. PolyPeptide currently manages 37 metabolic programs.
Novo Nordisk files lawsuit accusing rival Eli Lilly of running ‘false and misleading’ GLP-1 ads
Source ↗Novo Nordisk filed a lawsuit alleging Eli Lilly uses misleading clinical data in Zepbound and Mounjaro advertisements. The suit claims Lilly unfairly compares its drugs to lower-dose versions of Wegovy and Ozempic.
STAT+: Telemedicine company touted by Novo Nordisk stressed profits over patient safety, ex-workers say (paywalled)
Source ↗Former employees of a telehealth company promoted by Novo Nordisk say it put growth ahead of patient safety in how it prescribed GLP-1 weight-loss drugs, adding to scrutiny of online obesity-drug distribution.
Also covered by: stat_news
Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear
Source ↗While Eli Lilly’s retatrutide achieved 22.6% weight loss in Phase 3 trials, lower-than-expected cardiovascular event rates in the study population left the drug's impact on reducing major cardiovascular risks less conclusive.
Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
Source ↗Roche CEO Thomas Schinecker confirmed plans to test the obesity therapy petrelintide in combination with enicepatide (CT-388), the GLP-1/GIP dual agonist, expressing confidence in the company's metabolic pipeline.
Also covered by: globenewswire_pharma
Phase 4Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients
Yunlong Wang · 710 participants · TEAR-AF
Sponsor Yunlong Wang has registered a 710-patient Phase 4 trial evaluating tirzepatide's effect on atrial fibrillation recurrence following catheter ablation in obese patients.
Phase 3AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
Novo Nordisk A/S · 950 participants · AMAZE 9
Novo Nordisk has registered AMAZE 9, a 950-patient Phase 3 trial of zenagamtide (amycretin) tablets for weight loss. It is the first oral study in the AMAZE Phase 3 program, which has so far tested the injectable formulation.
Phase 1A Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults With Overweight or Obesity
Pfizer · 57 participants
Pfizer has registered a 57-patient Phase 1 trial to evaluate the pharmacokinetics and blood absorption of its candidate PF-08653945 in adults with overweight or obesity.
Early Phase 1A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity
Zealand Pharma · 88 participants
Zealand Pharma registered an 88-patient Phase 1 trial to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of its novel obesity candidate ZP6590.
Phase 1A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca · 152 participants
AstraZeneca launched a 152-patient Phase 1 study to investigate the relative bioavailability and safety of different oral formulations of elecoglipron in healthy participants.
Phase 1A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity
Amgen · 154 participants
Amgen has initiated a 154-patient Phase 1 clinical trial to assess the bioavailability of AMG 133 in participants living with overweight or obesity.
Know someone who'd find this useful?